2026
Conducting Phase II, III, and IV clinical trials across multiple oncology lines, supported by a strong track record in patient recruitment and data quality.
Full record of international multicenter clinical studies conducted by our team of Principal Investigators.
| Phase | Title | Sponsor |
|---|---|---|
| PHASE III | VIKTORIA-2 Phase 3 study of gedatolisib as first-line treatment for patients with HR-positive, HER2-negative advanced breast cancer (VIKTORIA-2) | Celcuity Inc |
| - | CAMBRIA-2 D8531C00001 Adjuvant endocrine therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer | AstraZeneca |
| - | BURAN AN2025H0301 on buparlisib (AN2025) in combination with paclitaxel versus paclitaxel monotherapy, for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. | Adlai Nortye Biopharma |
| - | CAPITELLO-292 D361DC00001 Randomized study of capivasertib in patients with locally advanced, unresectable, or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CAPItello-292) | AstraZeneca SA |
| - | CAMBRIA-1 D8531C00002 Study of camizestrant in ER+/HER2- early breast cancer after at least 2 years of standard adjuvant endocrine therapy | AstraZeneca |
| - | DESTINY-04 DS8201-A-U306: Trastuzumab deruxtecan for subjects with HER2-positive gastric or gastroesophageal junction adenocarcinoma after progression during or after a trastuzumab regimen | Daiichi Sankyo |
| - | J2J-MC-JZLH: A study of Imlunestrant versus standard endocrine therapy in patients with early breast cancer | Eli Lilly Interamérica Inc Sucursal Argentina |
| - | TROPION Breast02 D926PC00001 Randomized study of Dato-DXd in patients with triple-negative breast cancer (TROPION Breast02) | AstraZeneca |
| PHASE III | VIKTORIA-1 CELC-G-301 Phase 3 study of gedatolisib in patients with Rh-positive, HER2-negative advanced breast cancer (VIKTORIA-1) | PSI CRO SRL |
| - | MO43576 RANDOMIZED MULTICENTER OPEN-LABEL CROSSOVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL INFORMED PREFERENCE REGARDING SC ADMINISTRATION OF ATEZOLIZUMAB COMPARED TO IV FORMULATION IN PARTICIPANTS WITH NON-SMALL CELL LUNG CANCER | Productos Roche S.A.Q. e I. |
| PHASE I | C4391001 - Phase I/Ib study of PF-07220060 in participants with advanced solid tumors | Pfizer SRL |
| PHASE III | I3Y-MC-JPEF (postMONARCH) Phase III, randomized, double-blind, placebo-controlled study to compare the efficacy of abemaciclib plus fulvestrant with placebo plus fulvestrant in participants with HR+, HER2- advanced or metastatic breast cancer progressing on endocrine therapy and a CDK4/6 inhibitor | Eli Lilly Interamérica Inc Sucursal Argentina |
| PHASE III | J2J-OX-JZLC: EMBER-3: Phase III, randomized, open-label study of LY3484356 versus investigator's choice endocrine therapy in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, previously treated with endocrine therapy | Lilly |
| - | NTRK A study to evaluate the effect of Larotrectinib in adults and children with tumors positive for NTRK gene fusion. In Argentina, only over 18 years old. | Bayer |
| - | DESTINY-Breast09 D9670C00001: Study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) with or without pertuzumab compared to taxane, trastuzumab, and pertuzumab as first-line treatment in HER2-positive advanced or metastatic breast cancer. | AstraZeneca |
| - | DESTINY-BREAST06 D9770C0001 Study of Trastuzumab Deruxtecan in patients with HER2-low metastatic breast cancer that has progressed on endocrine therapy [DESTINY-BREAST06] | AstraZeneca |
| - | Study with Durvalumab for the Treatment of patients with non-small cell lung cancer with Minimal Residual Disease following Surgery and Curative Intent Therapy | AstraZeneca |
| - | Study of Durvalumab to evaluate efficacy in the Adjuvant setting combined with chemotherapy for non-small cell lung cancer. | AstraZeneca |
| PHASE III | I3Y-MC-JPCW eMonarcHER: Phase III study of abemaciclib plus standard adjuvant endocrine therapy in participants with high-risk, node-positive, HR+, HER2+ breast cancer | Lilly |
| - | FLAURA2 Study of osimertinib with or without platinum-based chemotherapy plus pemetrexed, as first-line treatment in locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation (FLAURA2) | AstraZeneca |
| - | GSK 209229: Study of GSK3359609 versus placebo in combination with pembrolizumab for the first-line treatment of recurrent/metastatic PD-L1 positive squamous cell carcinoma of the head and neck | GlaxoSmithKline |
| PHASE III | Randomized, double-blind, phase III study to evaluate the efficacy and safety of capivasertib + paclitaxel versus placebo + paclitaxel as first-line treatment for patients with histologically confirmed, locally advanced (inoperable), or metastatic triple-negative breast cancer | AstraZeneca |
| - | Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Non-Small Cell Lung Cancer | AstraZeneca |
| PHASE III | CDRB436F2410 Open-label, phase IIIb study of dabrafenib in combination with trametinib in the adjuvant treatment of BRAFV600 mutation-positive stage III melanoma | Novartis |
| PHASE III | Randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib, and trametinib versus the combination of placebo, dabrafenib, and trametinib in patients with unresectable or metastatic BRAF V600 mutant melanoma who have not received prior treatment | Novartis |
| PHASE III | PHASE 3 STUDY OF ADXS11-001 ADMINISTERED AFTER CHEMORADIATION AS ADJUVANT TREATMENT FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER: | Alzeca Biosciences |
| - | SOLAR-1 BYL719C2301 Alpelisib for PIK3CA Mutated, Hormone Receptor Positive Advanced Breast Cancer | Novartis |
| PHASE III | 3Y-MC-JPBZ monarcHER: Phase II, randomized, multicenter, 3-arm, open-label study to evaluate the efficacy of abemaciclib plus trastuzumab with or without fulvestrant compared to physician's choice standard chemotherapy plus trastuzumab in women with advanced breast cancer | Lilly |
| - | SELECT-1: Efficacy and safety of selumetinib in combination with docetaxel as second-line treatment for locally advanced or metastatic KRAS-positive non-small cell lung cancer (NSCLC) (stage IIIB-IV) | AstraZeneca |
| PHASE III | MO28048 - MULTINATIONAL, MULTICENTER, OPEN-LABEL, NON-RANDOMIZED, PROSPECTIVE, TWO-COHORT PHASE III STUDY TO EVALUATE THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB WITH ASSISTED ADMINISTRATION AND SELF-ADMINISTRATION AS ADJUVANT TREATMENT IN PATIENTS WITH OPERABLE HER2+ EARLY BREAST CANCER. | Roche |
| - | Saruparib (AZD5305) plus camizestrant compared to CDK4/6 inhibitor plus endocrine therapy or plus camizestrant in HR-positive, HER2-negative (IHC 0, 1+, 2+/ISH not amplified) BRCA1, BRCA2, or PALB2m advanced breast cancer | AstraZeneca |
| - | Study to evaluate ABP 206 compared to OPDIVO® (Nivolumab) in subjects with unresectable or metastatic melanoma | Bristol Myers Squibb |
| PHASE III | C4391022: INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OLDER THAN 18 YEARS WITH ADVANCED/METASTATIC BREAST CANCER | Pfizer SRL |
| - | ABP 206: Randomized, double-blind study evaluating the pharmacokinetic similarity of ABP 206 compared to OPDIVO® (nivolumab) in subjects with stage III or stage IV excised melanoma in the adjuvant setting | PAREXEL International S.A. |
| - | MB12-C-01-22: Multicenter, multinational, randomized, double-blind study to evaluate the pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) versus Keytruda® in subjects with stage IV non-squamous non-small cell lung cancer | Laboratorio Elea Phoenix S.A |
| - | MB12-C-01-22: Multicenter, multinational, randomized, double-blind study to evaluate the pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) versus Keytruda® in subjects with stage IV non-squamous non-small cell lung cancer | Syneos Health Argentina S.A. |
| PHASE II | CO44194 MULTICENTER RANDOMIZED AND DOUBLE-BLIND PHASE II STUDY OF RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED TO PEMBROLIZUMAB COMBINED WITH NAB-PACLITAXEL IN PARTICIPANTS WITH LOCALLY ADVANCED PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC PD-L1 POSITIVE TRIPLE-NEGATIVE BREAST CANCER | Productos Roche S.A.Q. e I. |
| PHASE III | C4891001_Open-Label Phase 3 Study of ARV-471 (PF-07850327) versus Fulvestrant in Participants with ER(+)/HER2 Advanced Breast Cancer (VERITAC-2) | Pfizer |
| PHASE III | INAVO 122 WO44263 PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF INAVO IN COMB WITH PHESGO VS PLACEBO IN COMB WITH PHESGO AS MAINT THERAPY AFTER 1st LINE INDUC THERAPY IN PARTICIPANTS WITH HER2+, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION | Roche |
| PHASE III | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Novartis Argentina S.A. |
| PHASE III | INAVO 121 WO43919- PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB+FULVESTRANT VERSUS ALPELISIB+FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR+, HER-2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA MUTATION | Roche |
| PHASE III | INAVO 120 WO41554 - PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INAVO + PALBO AND FULVESTRANT, VERSUS PLACEBO + PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH HER2-, LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WITH POSITIVE HORMONE RECEPTORS AND PIK3CA MUTATION. | Roche |
| PHASE III | BO42864 RANDOMIZED, OPEN-LABEL, PHASE III STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF METASTATIC, RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Roche |
| PHASE II | RC48-ADC Phase 2, multi-cohort, open-label, multicenter clinical study to evaluate the efficacy and safety of disitamab vedotin (RC48-ADC) in subjects with locally advanced unresectable or metastatic urothelial carcinoma with HER2 receptor expression | RemeGen Co |
| PHASE I/II | DZ2019E0001 WU Kong1 Phase I/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy of DZD9008 in patients with advanced non-small cell lung cancer (NSCLC) with EGFR or HER2 mutation | Dizheng Pharmaceutical |
| - | 20210104 - A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression | Amgen |
| PHASE III | MO43110 MULTINATIONAL MULTICENTER RANDOMIZED OPEN-LABEL PHASE IIIB STUDY EVALUATING PATIENT PREFERENCE FOR HOME ADMIN OF FIXED-DOSE COMBINATION PERTUZUMAB AND TRASTUZUMAB FOR SC ADMIN IN PARTICIPANTS WITH EARLY STAGE OR LOCALLY ADVANCED/INFLAMMATORY HER2-POSITIVE BREAST CANCER | Roche |
| PHASE III | HEREDERA WO43571 RANDOMIZED OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO COMPARED WITH PHESGO AFTER INDUCTION THERAPY WITH PHESGO PLUS TAXANE IN PTS WITH LOCALLY ADVANCED OR METASTATIC HER2+ AND ESTROGEN RECEPTOR+ BREAST CANCER WITHOUT PRIOR TTO | Roche |
| PHASE II | WO42312 RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GDC-9545 COMPARED WITH ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED, HER2-NEGATIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Roche |
| PHASE III | YO42137 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ATEZOLIZUMAB IN COMBINATION WITH TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) OR ALONE, IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING CHEMORADIOTHERAPY | Roche |
| PHASE III | J2G-MC-JZJC: Phase III Study comparing LOXO-292 to platinum- and pemetrexed-based therapy, with or without pembrolizumab (LIBRETTO-431) | Lilly |
| PHASE III | RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT, COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER | Nuvisan Pharma |
| - | TCD16210: Study of safety and efficacy of SAR442720 in combination with pembrolizumab in advanced malignancies | Sanofi-aventis |
| - | 213831: Comparison of efficacy and safety of niraparib with placebo in participants with HER2-negative breast cancer with BRCA mutation or triple-negative breast cancer with molecular disease based on the presence of ctDNA | GSK |
| - | AMEERA-5 EFC15935 Amcenestrant (SAR439859) plus palbociclib as first-line treatment for patients with ER(+), HER2(-) advanced breast cancer (AMEERA-5). | Sanofi-aventis |
| - | EPIKO CBYL719H12301: Study evaluating the efficacy and safety of alpelisib in combination with nab-paclitaxel in subjects with advanced triple-negative breast cancer with PIK3CA mutation or PTEN loss without PIK3CA mutation | Novartis |
| PHASE III | WO41994 - MULTICENTER, RANDOMIZED PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF ATEZOLIZUMAB WITH CABOZANTINIB VS CABOZANTINIB ALONE, FOR PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH TUMOR PROGRESSION | Roche |
| PHASE III | MO39193: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH EARLY RELAPSING TRIPLE-NEGATIVE BREAST CANCER (METASTATIC OR INOPERABLE LOCALLY ADVANCED) | Roche |
| PHASE III | BO41843 Multicenter, randomized, double-blind, placebo-controlled phase III study evaluating efficacy and safety of GDC-9545 combined with palbociclib versus letrozol combined with palbociclib in patients with HER2-NEG, estrogen receptor +, locally advanced or metastatic breast CA | Roche |
| - | 213400: Placebo-controlled study comparing niraparib plus pembrolizumab versus placebo and pembrolizumab as maintenance therapy | GSK |
| - | EFC15858-CARMEN- SAR408701 versus docetaxel in previously treated patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-positive metastatic non-squamous non-small cell lung cancer | Sanofi-aventis |
| - | Compare the effect of capivasertib + fulvestrant relative to placebo + fulvestrant by evaluating PFS in the overall population. | AstraZeneca |
| PHASE III | Randomized, double-blind, controlled Phase 3 study of Cabozantinib in combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in previously untreated patients with advanced or metastatic renal cell carcinoma of intermediate or poor risk | Bristol Myers Squibb |
| PHASE II | ACT16105 Phase II study of SAR439859 versus physician's choice of therapy in locally advanced or metastatic ER-positive breast cancer in pre-menopause or post-menopause | Sanofi-aventis |
| PHASE III | CO41101 - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER | Roche |
| PHASE III | Elacestrant monotherapy, compared with standard of care, in patients with ER+/HER2- advanced breast cancer who have previously received a CDK4/6 inhibitor: A randomized, open-label, active-controlled, multicenter, phase 3 trial (237119) | Menarini |
| PHASE II | Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer | Bristol Myers Squibb |
| PHASE III | Randomized, open-label, phase 3 study to evaluate enfortumab vedotin compared to chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer (EV-301) | Astellas |
| - | BO39633: MULTICENTER, OPEN-LABEL, LONG-TERM OBSERVATIONAL AND EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD SPONSORED ATEZOLIZUMAB STUDY | Roche |
| PHASE III | CO40016 - DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS TREATMENT FOR PATIENTS WITH TRIPLE-NEGATIVE OR HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH ALTERED PIK3CA/AKT1/PTEN | Roche |
| - | BO29554: STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD | Roche |
| - | CBYL719X2402 Study to evaluate the efficacy and safety of alpelisib plus fulvestrant or letrozol, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed during or after treatment with CDK 4/6 inhibitors | Novartis |
| PHASE III | RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PF-05280014 PLUS PACLITAXEL COMPARED WITH TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | Pfizer |
| PHASE III | WO40324 Two-arm, randomized, multicenter, open-label phase III study to evaluate the pharmacokinetics, efficacy, and safety of SC administration of the fixed-dose combination of pertuzumab and trastuzumab in comb. with chemotherapy in patients with early her2+ breast cancer | Roche |
| PHASE III | MO29872 OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED TO CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (STAGE IIIB NOT AMENABLE TO MULTIMODAL TREATMENT) OR META | Roche |
| PHASE III | I3Y-MC-JPCF Phase III, randomized, open-label study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with early-stage, high-risk, node-positive breast cancer, | Lilly |
| PHASE III | B7391003: RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PF-06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE PRIMARY TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | Pfizer |
| - | B9991001: Study of Avelumab in patients with advanced or metastatic urothelial cancer after completing first-line platinum-based chemotherapy | Pfizer |
| PHASE III | EGF114299 Alternative A phase III, randomized study that found dual Her 2 blockade using lapatinib trastuzumab plus Aromatase Inhibitor compared to single Her 2 blockade | GlaxoSmithKline |
| - | EGF117165. Study of biomarkers associated with response to subsequent therapies in patients with HER2-positive metastatic breast cancer treated with trastuzumab combined with lapatinib or chemotherapy. | GlaxoSmithKline |
| PHASE III | WO29522 - MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED TO PLACEBO WITH NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER | Roche |
| PHASE III | Global, randomized, open-label, multicenter, phase III study of combination therapy of MEDI4736 with Tremelimumab compared to standard treatment with platinum-based chemotherapy in patients receiving first-line treatment for advanced or metastatic lung cancer (NSCLC) | AstraZeneca |
| PHASE III | I5B-MC-JGDJ: Randomized, double-blind, placebo-controlled Phase 3 study with doxorubicin plus olaratumab versus doxorubicin plus placebo in patients with advanced or metastatic soft tissue sarcoma | Lilly |
| PHASE III | 4T-MC-JVDB: Randomized Phase 2 trial evaluating the pharmacokinetics and safety of four dose regimens of ramucirumab in the second-line treatment of gastric or gastroesophageal junction adenocarcinoma | Lilly |
| PHASE III | JUNIPER I3Y-MC-JPBK: Randomized Phase 3 study of abemaciclib plus best supportive care compared to Erlotinib plus best supportive care in patients with stage IV NSCLC with a detectable KRAS mutation who progressed after platinum-based chemotherapy | Lilly |
| - | MK3475-061 vs Paclitaxel in gastroesophageal adenocarcinoma. | MSD |
| PHASE III | COMBI-AD (GSK2118436) (GSK1120212): Phase III, randomized, double-blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. | GlaxoSmithKline |
| PHASE II/III | BO27952 - A RANDOMIZED, MULTICENTER, ADAPTIVE, PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER | Roche |
| - | BO22589 - 3-arm, multicenter study to evaluate the efficacy and safety of T-DM1 in combination with pertuzumab or T-DM1 in combination with pertuzumab placebo compared to the combination of trastuzumab plus taxane, as first-line treatment for breast cancer | Roche |
| PHASE III | EXELISIS XL092-304: Open-label, randomized phase 3 study to evaluate XL092 in combination with nivolumab compared to sunitinib in participants with advanced or metastatic clear cell (non-clear) renal cell carcinoma. | Exelisis |
| - | REGENERON 2055 R3767-ONC-2055 | Regeneron |
| PHASE III | TROPION 07 DS1062-A-U303: Randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd) and pembrolizumab, with or without platinum chemotherapy, in subjects without prior therapy for non-small cell lung cancer | AstraZeneca |
| - | Dato-DXd plus pembrolizumab versus pembrolizumab alone in the first-line treatment of subjects with advanced or metastatic NSCLC without actionable genomic alterations | AstraZeneca |
| PHASE III | HARMONY (REGN3767, anti-LAG-3): A Phase 3 study of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab, in patients with previously untreated, unresectable, locally advanced or metastatic melanoma. | Regeneron |
| - | Savolitinib plus osimertinib versus platinum-based doublet chemotherapy in participants with mutated EGFR and MET overexpression and/or amplification NSCLC who have progressed on osimertinib | AstraZeneca |
| PHASE III | Randomized, open-label, phase 3 study of tisotumab vedotin compared to investigator's choice chemotherapy in second or third line for recurrent or metastatic cervical cancer | Eli Lilly Interamérica Inc Sucursal Argentina |
| - | CYCLONE 3 I3Y-MC-JPEG: Study of abemaciclib with abiraterone in men with hormone-sensitive high-risk metastatic prostate cancer | Eli Lilly Interamérica Inc Sucursal Argentina |
Technical and general information for patients and referring physicians.
A medical research study in which volunteer patients participate. Its purpose is to evaluate whether a new treatment, such as a drug, targeted therapy, or immunotherapy, is safe and effective, with the goal of improving current standards of cancer care.
Yes. All protocols are strictly regulated by national health authorities and independent ethics committees. The absolute priority of the medical research team is the patient’s safety and well-being, and participants are monitored continuously.
Clinical trials are divided into consecutive stages to ensure the safety and effectiveness of treatments:
Please consult your oncologist, who can advise you on the criteria established by the study. Each protocol has strict inclusion requirements based on diagnosis, stage, and previous treatments.
No. If the patient meets the inclusion criteria and voluntarily decides to join the study, the investigational medication, diagnostic tests such as laboratory work and CT scans, and medical consultations related to the protocol are fully covered by the study sponsor.